Characterization of compound mechanisms and secondary activities by BioMAP analysis

Journal of Pharmacological and Toxicological Methods

Volumn 53, Issue 1, 2006, Pages 67-74

  Berg, Ellen L ^a   Kunkel, Eric J ^a   Hytopoulos, Evangelos ^a   Plavec, Ivan ^a  

^a BioSeek Inc   (United States)

Author keywords

Cell; Culture; Drug; Endothelial; Human; Lymphocyte; Mechanism; Methods; Monocyte; Primary

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; 5 (2 AMINO 4 PYRIMIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; ASTEMIZOLE; ATORVASTATIN; BAY 117085; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BUDESONIDE; CAPTOPRIL; COMPACTIN; CYCLOSPORIN A; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; ENZYME INHIBITOR; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; LISINOPRIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PREDNISOLONE; RADICICOL; RAPAMYCIN; RO 1069920; SC 514; SIMVASTATIN; SL 327; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; UO 126; WORTMANNIN;

ARTICLE; BIOASSAY; CELL CULTURE; CELL STIMULATION; CLUSTER ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LEUKOCYTE; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

BUTADIENES; CELLS, CULTURED; CLUSTER ANALYSIS; COCULTURE TECHNIQUES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; ENTEROTOXINS; ENZYME INHIBITORS; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MAP KINASE KINASE KINASES; NITRILES; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; REPRODUCIBILITY OF RESULTS; STAPHYLOCOCCUS AUREUS;

ANIMALIA;

EID: 30144436299     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2005.06.003     Document Type: Article

References (11)

1. E.L. Berg, E. Hytopoulos, I. Plavec, and E.J. Kunkel Approaches to the analysis of cell signaling networks and their application in drug discovery Current Opinion in Drug Discovery and Development 8 2005 107 114
2. E.C. Butcher Can cell systems biology rescue drug discovery? Nature Reviews Drug Discovery 4 2005 461 467
3. E.C. Butcher, E.L. Berg, and E.J. Kunkel Systems biology in drug discovery Nature Biotechnology 22 2004 1253 1259
4. L. Chen, W. Fischle, E. Verdin, and W.C. Greene Duration of nuclear NF-kappaB action regulated by reversible acetylation Science 293 2001 1653 1657
5. E.J. Kunkel, M. Dea, A. Ebens, E. Hytopoulos, J. Melrose, and D. Nguyen An integrative biology approach for analysis of drug action in models of human vascular inflammation FASEB Journal 18 2004 1279 1281
6. E.J. Kunkel, I. Plavec, D. Nguyen, J. Melrose, E.S. Rosler, and L.T. Kao Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models Assay and Drug Development Technologies 2 2004 431 441
7. J.M. Lehmann, J.M. Lenhard, B.B. Oliver, G.M. Ringold, and S.A. Kliewer Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs Journal of Biological Chemistry 272 1997 3406 3410
8. N.D. Perkins, L.K. Felzien, J.C. Betts, K. Leung, D.H. Beach, and G.J. Nabel Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator Science 275 1997 523 527
9. I. Plavec, O. Sirenko, S. Privat, Y. Wang, M. Dajee, and J. Melrose Method for analyzing signaling networks in complex cellular systems Proceedings of the National Academy of Sciences Sciences U S A 101 2004 1223 1228
10. J.D. Storey, and R. Tibshirani Statistical significance for genomewide studies Proceedings of the National Academy of Sciences U S A 100 2003 9440 9445
11. U.S. Food and Drug Administration Innovation or stagnation?-Challenge and opportunity on the critical path to new medical products http://www.fda.gov/oc/ initiatives/criticalpath/whitepaper.html 2004